开窗或分支腔内主动脉瘤修复术后的再干预
97%再干预成功,但再干预伴随显著并发症和死亡。
要点
- F/B-EVAR术后25%患者需再干预,III型内漏最常见(28%)。
- 再干预多经皮(67%)、住院(61%)进行,中位住院5天。
- 32例再干预患者中4例死亡<30天,其中3例判定与动脉瘤/再干预无关。
核心结论
- F/B-EVAR术后26%患者需再干预,最常见为III型内漏和靶动脉并发症。
- 除1例外再干预均成功,但许多再干预为复杂操作,伴随显著并发症和死亡。
- 作者认为改进组件连接完整性以消除III型内漏、确保靶动脉一期通畅是F/B-EVAR演进的关键下一步。
研究设计与样本
- 单中心、经机构审查委员会批准的前瞻性登记数据库,纳入 physician-sponsored investigational device exemption 试验(G130210)患者,回顾分析2010年11月至2016年12月连续123例F/B-EVAR。
- 再干预定义为任何动脉瘤相关、装置相关或靶动脉相关操作,同一患者多次再干预每次计为独立事件。
- 再干预成功定义为指征解除。
主要发现
- 123例F/B-EVAR(平均随访25个月)中,32例(25%)接受54次再干预;20例(63%)1次、6例(19%)2次、4例(13%)3次、1例(3.1%)4次、1例(3.1%)6次。
- 最常见指征为III型内漏(n=15,28%)、靶动脉闭塞(n=7,13%)和狭窄(n=6,11%)。
- 再干预在围手术期、短期和中期分别占17%、41%和43%。
- 再干预方式经皮67%、住院61%,中位住院5天;32例再干预患者中4例出现入路部位并发症,4例在再干预后<30天死亡(其中3例判定与动脉瘤/再干预无关)。
- 31/32(97%)患者再干预成功。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Reinterventions after fenestrated or branched endovascular aneurysm repair (F/B-EVAR) are sometimes necessary to maintain aneurysm exclusion or endograft and target artery patency. These reinterventions are nontrivial, potentially associated with morbidity, mortality, and resource utilization. Whereas rates, types, and outcomes of reintervention after infrarenal EVAR have been well described, they have not been well described for F/B-EVAR. We sought to characterize the morbidity, mortality, and resource utilization due to reinterventions after F/B-EVAR. METHODS: All F/B-EVAR variables collected prospectively through a single-institution, Institutional Review Board-approved registry, which included patients enrolled in a physician-sponsored investigational device exemption trial (G130210), were reviewed (November 2010-December 2016). Reinterventions were defined as any procedure that was aneurysm related, device related, or target artery related. For patients with more than one reintervention, each intervention occurrence was treated as a discrete event. Reintervention type, indication, timing (perioperative, days 0-30; short term, days 31-180; midterm, >180 days), inpatient/outpatient, length of stay, and morbidity/mortality were recorded. Reintervention success was defined as resolution of the indication. RESULTS: Among 123 consecutive F/B-EVARs (mean follow-up, 25 months), 32 patients (25%) underwent 54 reinterventions (one reintervention, 20 (63%) patients; two reinterventions, 6 (19%) patients; three reinterventions, 4 (13%) patients; four reinterventions, 1 (3.1%) patient; and six reinterventions, 1 (3.1%) patient). The most frequent indications were type III endoleaks (n = 15 [28%]), target artery occlusions (n = 7 [13%]), and stenoses (n = 6 [11%]). These were performed in the perioperative, short-term, and midterm time frames 17%, 41%, and 43% of the time, respectively. Reinterventions were percutaneous (67%), inpatient procedures (61%), with median length of stay of 5 days. Of the 32 reintervention patients, 4 experienced access site complications and 4 died <30 days after reintervention (3 were adjudicated as not aneurysm related/not reintervention related). In 31 of 32 (97%) patients, reintervention success was achieved. CONCLUSIONS: Reinterventions after F/B-EVAR were necessary in 26% of patients, most commonly for type III endoleaks and target artery complications. Whereas all but one reintervention was successful, many of these required complex procedures with significant morbidity and mortality. Development of strategies to eliminate type III endoleaks by improving component junction integrity and to ensure target artery primary patency are key next steps in the evolution of F/B-EVAR.
引用
- Dossabhoy SS, Simons JP, Diamond KR, et al. Reinterventions after fenestrated or branched endovascular aortic aneurysm repair. J Vasc Surg. 2018. PMID: 29523438. doi:10.1016/j.jvs.2017.12.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。